Halozyme Therapeutics, Inc. (LON:0J2O)
London · Delayed Price · Currency is GBP · Price in USD 63.16
+1.48 (2.41%)
At close: Aug 8, 2025
Halozyme Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 1,179 | 1,015 | 829.25 | 660.12 | 443.31 | 267.59 | Upgrade | |
Revenue Growth (YoY) | 34.97% | 22.44% | 25.62% | 48.91% | 65.66% | 36.53% | Upgrade |
Cost of Revenue | 265.29 | 238.47 | 268.72 | 205.91 | 117.09 | 77.6 | Upgrade |
Gross Profit | 913.38 | 776.86 | 560.53 | 454.21 | 326.23 | 189.99 | Upgrade |
Selling, General & Admin | 167.47 | 154.34 | 149.18 | 121.63 | 50.32 | 45.74 | Upgrade |
Operating Expenses | 230.71 | 225.38 | 220.46 | 164.77 | 50.32 | 45.74 | Upgrade |
Operating Income | 682.67 | 551.48 | 340.07 | 289.43 | 275.9 | 144.26 | Upgrade |
Interest Expense | -17.98 | -18.1 | -18.76 | -16.95 | -7.53 | -20.38 | Upgrade |
Interest & Investment Income | 19.07 | 12.83 | 10 | 3.88 | 3.36 | 5.43 | Upgrade |
EBT Excluding Unusual Items | 683.76 | 546.21 | 331.31 | 276.36 | 271.74 | 129.3 | Upgrade |
Merger & Restructuring Charges | - | - | - | -21.9 | - | - | Upgrade |
Gain (Loss) on Sale of Investments | 8.37 | 10.93 | 6.32 | -2.83 | -2.26 | - | Upgrade |
Asset Writedown | - | - | -2.5 | - | - | - | Upgrade |
Other Unusual Items | - | - | 13.2 | -2.71 | -20.96 | - | Upgrade |
Pretax Income | 692.13 | 557.13 | 348.33 | 248.92 | 248.52 | 129.3 | Upgrade |
Income Tax Expense | 134.85 | 113.04 | 66.74 | 46.79 | -154.19 | 0.22 | Upgrade |
Net Income | 557.28 | 444.09 | 281.59 | 202.13 | 402.71 | 129.09 | Upgrade |
Net Income to Common | 557.28 | 444.09 | 281.59 | 202.13 | 402.71 | 129.09 | Upgrade |
Net Income Growth | 65.22% | 57.71% | 39.31% | -49.81% | 211.97% | - | Upgrade |
Shares Outstanding (Basic) | 124 | 127 | 132 | 137 | 141 | 136 | Upgrade |
Shares Outstanding (Diluted) | 128 | 129 | 134 | 141 | 147 | 141 | Upgrade |
Shares Change (YoY) | -2.50% | -3.56% | -4.56% | -4.21% | 3.77% | -1.99% | Upgrade |
EPS (Basic) | 4.48 | 3.50 | 2.13 | 1.48 | 2.86 | 0.95 | Upgrade |
EPS (Diluted) | 4.37 | 3.43 | 2.10 | 1.44 | 2.74 | 0.91 | Upgrade |
EPS Growth | 68.93% | 63.33% | 45.83% | -47.45% | 201.10% | - | Upgrade |
Free Cash Flow | 540.69 | 468.37 | 373.28 | 235.3 | 297.98 | 52.95 | Upgrade |
Free Cash Flow Per Share | 4.24 | 3.62 | 2.78 | 1.67 | 2.03 | 0.37 | Upgrade |
Gross Margin | 77.49% | 76.51% | 67.59% | 68.81% | 73.59% | 71.00% | Upgrade |
Operating Margin | 57.92% | 54.32% | 41.01% | 43.84% | 62.24% | 53.91% | Upgrade |
Profit Margin | 47.28% | 43.74% | 33.96% | 30.62% | 90.84% | 48.24% | Upgrade |
Free Cash Flow Margin | 45.87% | 46.13% | 45.01% | 35.64% | 67.22% | 19.79% | Upgrade |
EBITDA | 758.6 | 627.09 | 416.93 | 336.07 | 277.3 | 145.84 | Upgrade |
EBITDA Margin | 64.36% | 61.76% | 50.28% | 50.91% | 62.55% | 54.50% | Upgrade |
D&A For EBITDA | 75.93 | 75.61 | 76.86 | 46.64 | 1.4 | 1.58 | Upgrade |
EBIT | 682.67 | 551.48 | 340.07 | 289.43 | 275.9 | 144.26 | Upgrade |
EBIT Margin | 57.92% | 54.32% | 41.01% | 43.84% | 62.24% | 53.91% | Upgrade |
Effective Tax Rate | 19.48% | 20.29% | 19.16% | 18.80% | - | 0.17% | Upgrade |
Revenue as Reported | 1,179 | 1,015 | 829.25 | 660.12 | 443.31 | 267.59 | Upgrade |
Updated Feb 18, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.